PODD News and Press, Insulet Corporation From 03/20/24

2024-03-20 06:46:19 ET More on Insulet Insulet: An Interesting, Yet Expensive, Story Insulet Omnipod 5 insulin pump bests conventional delivery systems Insulet Non-GAAP EPS of $1.40 beats by $0.74, revenue of $509.8M beats by $48.74M Seeking Alpha’s Qu...

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced that Ana Maria Chadwick has been appointed Executive Vice President, Chief Financial Officer and Treasurer, effecti...

2024-03-08 08:43:37 ET More on Insulet Insulet Corporation (PODD) Q4 2023 Earnings Call Transcript Insulet: An Interesting, Yet Expensive, Story Insulet Non-GAAP EPS of $1.40 beats by $0.74, revenue of $509.8M beats by $48.74M Insulet Q4 2023 Earnings Preview...

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today presented positive results from its first randomized controlled trial (RCT) showing improved glycemic and patient-reported ou...

Conducted in the United States and France, the OP5-003 Trial is the first Omnipod 5 study to include international participants. The OP5-003 Trial Presentation and Insulet Symposium will convey the importance of automated insulin delivery (AID) technology as Standard of Care. ...

2024-03-04 10:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-02-22 19:55:21 ET Insulet Corporation (PODD) Q4 2023 Results Conference Call February 22, 2024 04:30 PM ET Company Participants Deborah Gordon - Vice President, Investor Relations Jim Hollingshead - President & Chief Executive Officer Lauren Budden - Int...

2024-02-22 19:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-02-22 16:33:22 ET Insulet press release ( NASDAQ: PODD ): Q4 Non-GAAP EPS of $1.40 beats by $0.74 . Revenue of $509.8M (+37.9% Y/Y) beats by $48.74M . Total Omnipod revenue of $501.0 million, an increase of 36.7%, or 35.4% in constant currency U.S. ...

Represents 8th Consecutive Year of 20% or More Constant Currency Revenue Growth Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced financial results for t...